LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Ruea-Yea Huang1, 2, Cheryl Eppolito1, 2, Shashikant Lele1, Protul Shrikant4, Junko Matsuzaki1, 2, 3, Kunle Odunsi1, 2, 3 1Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA 2Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA 3Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York, USA 4Department of Research, Mayo Clinic, Scottsdale, Arizona, USA Correspondence to: Kunle Odunsi, e-mail: kunle.odunsi@roswellpark.org Ruea-Yea Huang, e-mail: raya.huang@roswellpark.org Keywords: LAG3, PD1, antibody blockade, T cell signaling, ovarian cancer Received: March 05, 2015 Accepted: July 10, 2015 Published: July 23, 2015